November 2021 | Volume 1
Lived experience is a powerful resource. Patients, families and caregivers have insights about goals, impact of care (or lack of it), and the social needs that make health possible. If we acknowledge that patient experience is important, then why are we notoriously bad at measuring and including such data in our research, our care delivery and our payment strategies? The excuse that "it’s complicated" should no longer be an acceptable answer. Patients from across disease communities are leading research and working with regulators to redefine when and how patient expertise informs everything from new therapies to the design and deliver of health benefits. It’s a promising trend.
For people with sickle cell disease, add check-ins to checkups
Among the many lessons the Covid-19 pandemic has taught society are that individual behaviors matter; leadership counts; and the burden of Covid-19 is not equally distributed. I’ve learned something more as a health care provider taking care of patients with sickle cell disease: Successfully caring for a vulnerable population with a chronic illness requires more than high-quality medical care.
The Key to Addressing Rising Health Care Costs Is Patient-Centered Evidence
Few issues inspire more bipartisan concern than the rising cost of health care in the United States. To address this challenge, we must recognize that it is rooted in a simple fact: The overwhelming share of our health spending, 71 percent, goes toward care to help people living with multiple chronic conditions.
Management of High-Need, High-Cost Patients: A “Best Fit” Framework Synthesis, Realist Review, and Systematic Review
In the United States, patients referred to as high-need, high-cost (HNHC) constitute a very small percentage of the patient population but account for a disproportionally high level of healthcare use and cost.
First-Hand Perspectives in Rheumatoid Arthritis
The Innovation and Value Initiative (IVI) and the Arthritis Foundation (AF) partnered with individuals living with rheumatoid arthritis (RA) to explore how insights from firsthand patient experiences can inform healthcare research, specifically its application to value assessment (also referred to as health technology assessment).
FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
The U.S. Food and Drug Administration, the National Institutes of Health, 10 pharmaceutical companies and five non-profit organizations have partnered to accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease. While there are approximately 7,000 rare diseases, only two heritable diseases currently have FDA-approved gene therapies.

Passion + Quality = Change That Matters
I embrace the powerful opportunities in our evolving health care landscape. I founded Momentum Health Strategies to be a catalyst for change through continuous learning, diverse engagement and thoughtful policy and practice initiatives. I deliver innovative, strategic thinking and a passion for improving the patient experience. My personal drive and dedication to high-quality results will help you navigate the competitive terrain you face and convert your vision to action.

Momentum Health Strategies

Jennifer L Bright, MPA
(703) 628 - 0534